# Hartmut Schmidt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hartmut-schmidt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,086 |
| Field | Medical and Health Sciences Research |
| h-index | 63 |
| i10-index | 249 |
| Last Known Institution | University Hospital Münster |
| OpenAlex ID | https://openalex.org/A5015932441 |
| ORCID iD | https://orcid.org/0000-0002-2402-7764 |
| Works | 1,035 |

## Researcher papers

- [Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis](https://scholariq.org/papers/patisiran-an-rnai-therapeutic-for-hereditary-transthyretin-amyloidosis/)
- [Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors](https://scholariq.org/papers/impaired-glucose-tolerance-beta-cell-function-and-lipid-metabolism-in-hiv/)
- [Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis](https://scholariq.org/papers/chymotrypsin-c-ctrc-variants-that-diminish-activity-or-secretion-are-associated/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Variants in CPA1 are strongly associated with early onset chronic pancreatitis](https://scholariq.org/papers/variants-in-cpa1-are-strongly-associated-with-early-onset-chronic-pancreatitis/)
- [A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis](https://scholariq.org/papers/a-degradation-sensitive-anionic-trypsinogen-prss2-variant-protects-against/)
- [Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome](https://scholariq.org/papers/association-between-grade-of-acute-on-chronic-liver-failure-and-response-to/)
- [Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study](https://scholariq.org/papers/long-term-safety-and-efficacy-of-patisiran-for-hereditary-transthyretin-mediated/)

## Researcher topics

- [Medical and Health Sciences Research](https://scholariq.org/topics/medical-and-health-sciences-research/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Organ Transplantation Techniques and Outcomes](https://scholariq.org/topics/organ-transplantation-techniques-and-outcomes/)

## Researcher university

- [University Hospital Münster](https://scholariq.org/institutions/university-hospital-munster/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.